<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Rev</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Rev</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drug and alcohol review</journal-title></journal-title-group><issn pub-type="ppub">0959-5236</issn><issn pub-type="epub">1465-3362</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10336643</article-id><article-id pub-id-type="pmcid-ver">PMC10336643.1</article-id><article-id pub-id-type="pmcaid">10336643</article-id><article-id pub-id-type="pmcaiid">10336643</article-id><article-id pub-id-type="manuscript-id">NIHMS1915535</article-id><article-id pub-id-type="pmid">32748413</article-id><article-id pub-id-type="doi">10.1111/dar.13129</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1915535</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1915535</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>US national treatment admissions with opioids and benzodiazepines</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8167-6955</contrib-id><name name-style="western"><surname>ARFKEN</surname><given-names initials="CL">CYNTHIA L.</given-names></name><degrees>PhD</degrees><role>Professor</role><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>OWENS</surname><given-names initials="DD">DARLENE D.</given-names></name><degrees>MBA, LBSW</degrees><role>Director of Substance Use Disorders</role><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>GREENWALD</surname><given-names initials="MK">MARK K.</given-names></name><degrees>PhD</degrees><role>Professor</role><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, USA</aff><aff id="A2"><label>2</label>Detroit Wayne Integrated Health Network, Detroit, USA</aff><aff id="A3"><label>3</label>Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, USA</aff><author-notes><corresp id="CR1">Correspondence to: Dr Cynthia L. Arfken, Department of Psychiatry and Behavioral Neurosciences, 3901 Chrysler Service Drive, Detroit, MI 48201, USA. Tel: +1 313 993 3940, Fax: +1 313 577 8823; <email>carfken@med.wayne.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>03</day><month>8</month><year>2020</year></pub-date><volume>39</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">440520</issue-id><fpage>862</fpage><lpage>869</lpage><pub-history><event event-type="nihms-submitted"><date><day>07</day><month>07</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>12</day><month>07</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>12</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 13:25:13.573"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1915535.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction and Aims.</title><p id="P1">Opioids and benzodiazepines (O/BZD) are increasingly involved in drug overdose deaths in the USA. Expanding treatment capacity may reduce these deaths. Knowledge about co-occurring O/BZD admissions compared to opioid admissions (opioid) is needed to plan this expansion.</p></sec><sec id="S2"><title>Design and Methods.</title><p id="P2">US treatment admissions to specialty facilities for 2011&#8211;2017 were analysed for trends and 2017 for group differences. Due to 1.9 million admissions in 2017, comparisons between O/BZD and opioid admissions were summarised as effect sizes. Additional analysis compared the administratively pre-coded category &#8216;other opiates and synthetics&#8217; to other opiates and synthetics/benzodiazepines admissions to control for possible similarity in drug source. Differences within O/BZD admissions by primary drug were explored.</p></sec><sec id="S3"><title>Results.</title><p id="P3">Although opioid admissions showed a steady increase over time (25.9% to 38.2%), O/BZD admissions showed increases until decline in 2017 (3.2% to 4.0%). In 2017 no factor reached moderate effect size (&#8805;0.2) in group comparisons or within the O/BZD admissions. Heroin was self-reported in 70% of both O/BZD and opioid admissions.</p></sec><sec id="S4"><title>Discussion and Conclusions.</title><p id="P4"><italic toggle="yes">No meaningful US national differences on data routinely collected were found for O/BZD compared to opioid admissions including the subgroup with other opiates and synthetics only. Efforts to expand existing opioid treatment in specialty treatments may help reduce opioid and O/BZD deaths. However, the analysis could not address whether changes in treatment would improve outcomes</italic>. [Arfken CL, Owens DD, Greenwald MK. US national treatment admissions with opioids and benzodiazepines. <italic toggle="yes">Drug Alcohol Rev</italic> 2020]</p></sec></abstract><kwd-group><kwd>opioid</kwd><kwd>benzodiazepine</kwd><kwd>treatment</kwd><kwd>admission</kwd><kwd>injection</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>